Phase III Lucanix™ Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line Chemotherapy (STOP)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
NovaRx Corporation
ClinicalTrials.gov Identifier:
NCT00676507
First received: May 8, 2008
Last updated: May 6, 2015
Last verified: May 2015